Lilly, citing FDA feedback, won't seek speedy approval of Alzheimer's drug

An Eli Lilly executive said on a conference call Tuesday that the company won't seek an accelerated U.S. review of its experimental Alzheimer's disease drug donanemab based on Phase 2 data the company disclosed last month.